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Background. Considerable differences exist among the living donor Kidney Exchange Programmes (KEPs) that are in 
use and being built in Europe, contributing to a variation in the number of living donor transplants (Newsletter Transplant; 
International figures on donation and transplantation 2016). Efforts of European KEPs to exchange (best) practices and 
share approaches to address challenges have, however, been limited. Methods. Experts from 23 European countries, 
collaborating on the European Network for Collaboration on Kidney Exchange Programmes Cooperation on Science and 
Technology Action, developed a questionnaire to collect detailed information on the functioning of all existing KEPs in 
Europe, as well as their opportunities and challenges. Following a comparative analysis, results were synthesized and 
interpreted by the same experts. Results. The practices, opportunities and challenges reported by 17 European countries 
reveal that some of the 10 operating programs are mature, whereas others are in earlier stages of development. Over 1300 
transplants were performed through existing KEPs up to the end of 2016, providing approximately 8% of their countries’ 
living kidney donations in 2015. All countries report challenges to either initiating KEPs or increasing volumes. Some chal-
lenges are shared, whereas others differ because of differences in context (eg, country size, effectiveness of deceased donor 
program) and ethical and legal considerations (eg, regarding living donation as such, nonrelated donors, and altruistic dona-
tion). Transnational initiatives have started in Central Europe, Scandinavia, and Southern Europe. Conclusions. Exchange 
of best practices and shared advancement of national programs to address existing challenges, aided by transnational 
exchanges, may substantially improve access to the most (cost) effective treatment for the increasing number of patients 
suffering from kidney disease.
(Transplantation 2019;103:1514–1522)
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For patients suffering from end-stage renal disease (ESRD), living donor kidney transplantation (LDKT) 
is more (cost) effective than deceased donor transplanta-
tion and dialysis.1-3 In particular, it yields better patient 
and graft survival.4 Over the past 2 decades, many coun-
tries have developed or intensified LDKT programs, often 
to supplement shortages in supply of donor organs for 
deceased donor programs. Other countries however, still 
largely rely on deceased donor programs. As of 2015, 
LDKT accumulates to 40% of approximately 80000 kid-
ney transplantations worldwide.5
The differences in adoption and implementation of 
LDKT programs in Europe result in a variation from 0 to 
33.2 in the number of living donor transplants per million 
inhabitants per year.6 This variation indicates that initiat-
ing and advancing KEPs can bring the benefit of treating 
more European ESRD patients, and/or treating them more 
(cost)-effectively.
Originally, LDKT was only feasible for patients with 
intended living donors of compatible blood group and 
HLA type. Depending on the country, 40% or more of 
recipients are incompatible with their intended donors.5 
Kidney Exchange Programmes (KEPs) enable transplanta-
tion for recipients who are blood- and/or HLA incompati-
ble with their initially intended donors. These incompatible 
pairs can join a larger pool of recipient-donor pairs, within 
which recipients may exchange donors. The KEP manage-
ment identifies matching donors for the recipients and 
arranges the transplantations to take place. Many coun-
tries across the globe, and specifically in Europe, are estab-
lishing KEPs and facing a variety of common challenges.7 
Additionally, some of the countries with existing KEPs 
appear to face challenges in increasing transplant numbers, 
despite considerable demand. Hence, there appears to be 
much to gain from collaboration and mutual learning.
The Cooperation on Science and Technology Association 
funds such a collaboration and mutual-learning project, 
namely the European Network for Collaboration on 
Kidney Exchange Programmes (ENCKEP) Cooperation 
on Science and Technology (COST) Action.8 The COST 
Association is a European framework whose actions are 
open to all 36 member-states, which is a wider set of coun-
tries than the EU and includes, eg, Norway and Turkey.9 
In addition, participation is possible from Cooperating 
State Israel, Near Neighbor Countries, and International 
Partner Countries. Hence, we have used a wider definition 
of Europe in this article, allowing also collaboration with 
and mutual learning from non-European countries.
ENCKEP started on September 1, 2016, bringing 
together policy makers, clinicians, and optimization 
experts from 27 participating countries at the time of writ-
ing. The aims of ENCKEP are to (1) Exchange best prac-
tices and scientific state of the art with respect to national 
KEPs; (2) Develop a jointly used common framework for 
data and optimization; (3) Develop and test a prototype 
for transnational KEPs; (4) Stimulate European policy dia-
logue on this topic. In this study, we report on research 
conducted to achieve the first aforementioned aim. We 
provide a comparative analysis of Europe’s current KEP 
practices and challenges.
MATERIALS AND METHODS
To systematically describe current KEP practices in 
Europe, a questionnaire has been developed to identify 
similarities and differences between countries, and future 
challenges. The questionnaire did not include individ-
ual patient or donor data and therefore no ethics board 
approval was needed.
The questionnaire was based on an earlier question-
naire that had been designed for the European Committee 
on Organ Transplantation within the Council of Europe 
(CD-P-TO).10 This original questionnaire was reviewed, 
amended, and restructured, following expert panel discus-
sion and involving representatives from the participating 
countries. These discussions were conducted partly at the 
first workshop of the COST Action in January 2017,8 where 
most of the operating European KEPs were presented, and 
their main features were identified. The detailed written 
reports of the discussion were subsequently restructured 
into a new questionnaire by a smaller expert group, and 
then distributed for improvement suggestions to ENCKEP 
participants, resulting in a final commonly approved ques-
tionnaire. The questionnaire was divided into sections 
focusing on:
–Short country description
–Numbers of registration and transplantation
–Activities
–Challenges and opportunities.
The questionnaires were sent to representatives of the 
ENCKEP countries in February 2017, who were asked to 
address all questions applicable to their country by March 
2017. The data collected through the questionnaires were 
systematically presented and subsequently synthesized 
into conclusions and recommendations in a workshop 
in March 2017,8 by representatives of the participat-
ing countries, as described in detail in the first ENCKEP 
Handbook.11 Below, we first present the main results from 
the questionnaires as viewed and prioritized during these 
workshops. The reflections and interpretations formed 
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during these workshops are included in the Discussion and 
Conclusions.
RESULTS
In total, 17 of the 23 countries participating in ENCKEP 
completed the questionnaire. Countries were classified 
according to the level of development of their KEPs into 
4 categories: (1) large, advanced programs, (2) smaller 
operational programs, (3) programs in preparation, and 
(4) countries without KEPs (Figure 1).
Short Country Descriptions Based on the Responses 
from the Questionnaire
The Netherlands has the highest number of living kid-
ney donations in Europe per million population (pmp), 
and was the first country in Europe to establish a nation-
ally coordinated KEP in 2004. The program is coordinated 
by the Dutch Transplant Foundation in close collaboration 
with 8 transplant centers and a single Central Reference 
Laboratory for histocompatibility testing. From 2004 
through 2016, the Dutch KEP has resulted in 284 trans-
plants, facilitating exchanges up to 4 pairs.12-23 The UK 
Living Kidney Sharing Schemes includes all 4 nations 
(England, Wales, Scotland, Northern Ireland) and has 
been operational since 2007. It was made possible by the 
Human Tissue Acts 2004 (England, Northern Ireland, and 
Wales) and 2006 (Scotland). The program is administered 
by NHS Blood and Transplant and involves 23 transplant 
centers and 20 histocompatibility and immunogenetics 
(H&I) laboratories. It has become the largest operat-
ing KEP in Europe, with 250 recipient-donor pairs reg-
istered per matching run, and a total of 658 transplants 
reported.24-26 The Spanish national program was devel-
oped in 2009 by Organización Nacional de Transplantes 
involving 25 of the 39 transplant centers and 18 H&I lab-
oratories in the country. The Spanish program is the sec-
ond largest KEP in Europe after the United Kingdom with 
110 donor-recipient pairs registered per matching run, and 
a total of 147 transplants reported.
As regard smaller programs, the Austrian KEP started in 
2013 with 4 participating transplant centers, coordinated 
by the Medical University of Vienna, with immunological 
testing on-site.27 After conducting 11 transplants through 
4 2-way exchanges and 1 3-way exchange between 2013 
and 2016, Austria joined the Czech Republic to create 
1 pool, and the first reported transnational exchange 
was performed in September 2016.28 The KEP in the 
Czech Republic started in 2011 and is organized by a 
single center, the Institute for Clinical and Experimental 
Medicine Prague. Despite the limited pool size, 60 trans-
plants were performed.29 The reasons for this high num-
ber of transplants are: the flexibility in performing long 
exchanges nonsimultaneously (the Czech Republic has 
conducted 6- and 7-way exchanges), the fast laboratory 
testing that facilitates rematching in response to positive 
crossmatch tests, the involvement of altruistic donors and 
compatible pairs, and the possibility of performing ABOi 
and HLAi transplants after desensitization within the 
KEP. The Polish program started in 2015, organized by 
FIGURE 1. Development of KEPs by country.
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surgeons from the Department of General and Transplant 
Surgery, Medical University of Warsaw. Five transplants 
(through one 2-way and one 3-way exchange) had been 
performed in a single center (Warsaw) by 2016 and 
the first interhospital exchange was performed in 2017 
between 2 centers.
The Belgian Living Donor Exchange Protocol was 
accepted in 2008 and the national KEP started in 2013, 
organized by the Kidney-Pancreas Committee and the 
Belgian Transplantation Society. The size of the pool is still 
limited, and 7 transplants have been reported through 2 
2-way exchanges and 1 3-way exchange. The French KEP 
started in 2013, organized by the Agence de la Biomédecine. 
A total of 67 patients have been registered with a total of 
10 transplants performed in 2-way exchanges. Altruistic 
donation is not legal in France, and exchanges involving 
more than 2 pairs are not yet allowed. The Italian KEP, run 
by the Italian National Transplant Centre, was established 
in 2006, but until 2014 only single-center exchanges were 
performed in the Pisa and Siena centers, achieving a total 
of 15 transplants. Since 2015 a further 16 transplants were 
conducted through long, but almost simultaneous, altruis-
tic donor chains, involving up to 11 centers. The national 
KEP in Portugal started in 2010, administered by Instituto 
Português do Sangue e da Transplantação. Five transplant 
centers out of 8 and 3 H&I laboratories are participating. 
Fifty patients were registered and a total of 9 transplants 
were reported by the end of 2016.
In several countries the KEPs have just been created or 
are in preparation. Sweden started its national KEP in 2016. 
In 2017, the initiative was taken up by Scandiatransplant, 
under the name of ScandiaTransplant Kidney Exchange 
Program, involving Sweden, Denmark, and Norway. A 
matching policy has been agreed and 2-way exchanges are 
currently allowed.30 However, no transplants have been 
performed yet. In Switzerland, kidney exchange has been 
regulated by the Swiss Transplantation Law since 2007, 
but only a few ad hoc 2- and 3-way exchanges have been 
performed so far. In fact, in 1999, Europe’s first kidney 
exchange was carried out in Switzerland. However, there 
were legislative and organizational restrictions. Since these 
are solved, the Swiss KEP is expected to start in 2018.31 In 
Greece, a national KEP will be established by the Hellenic 
Transplant Organization (EOM) in the near future, involv-
ing 5 kidney transplant centers. There is no national KEP 
in Slovakia yet, but there have been 7 ad hoc 2-way 
exchanges between 2005 and 2015. Among those, 6 were 
performed in single centers (within 3 of the 4 transplant 
centers in Slovakia) and 1 exchange was between 2 centers.
We have no information on other operating KEPs in 
Europe. However, Romania had a single center KEP in 
Cluj-Napoca from 2001.32,33 Between 2001 and 2005, 
their medical team performed 56 transplants through 23 
2-way exchanges, two 3-way exchanges and one 4-way 
exchange.
Regarding the countries that provided responses to 
our survey, but had no KEPs, Finland and Iceland are 
part of Scandiatransplant but they do not participate in 
ScandiaTransplant Kidney Exchange Program yet. Kidney 
exchange is not legally allowed in Finland; the Helsinki 
center performs all LDKT in the country. The LDKT pro-
gram in Iceland is supported by a visiting surgeon from the 
United States, and patients travel to Sweden for a deceased 
donor kidney transplant (DDKT). Recipient-donor pairs 
of Ireland can register through a UK transplant center for 
entry into UK Living Kidney Sharing, altogether 6 trans-
plants have been performed by that route.
Statistics and Comparisons
Regarding 12-month performance, the number of regis-
trations and the number of transplantations conducted in 
2015 can be seen in Figure 2.
The active KEPs in all 10 countries listed are organized 
centrally, although in the Czech Republic and Poland, 
the programs initially operated in the capitals, but they 
are now enlarging. Regarding legal restrictions, altru-
istic donation is not possible in France, Poland, Greece 
and Switzerland. In France and Portugal, only incom-
patible pairs can participate in the KEP. In France, only 
2-way exchanges are possible. In principle, nonresident 
FIGURE 2. KEP activity: number of proceeding transplants and the number of new recipients registered in 2015 by country.
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donor-recipient pairs can be involved in the majority of 
the KEPs except Portugal, where only resident recipients 
can join the KEP, and Belgium, where the recipient must 
be resident in a Eurotransplant country. Anonymity is 
a legal requirement in most countries and it is part of 
the protocol in all countries, except Poland. Compatible 
pairs can participate in KEPs in the advanced programs. 
In Spain, both pediatric recipients and compatible pairs 
are prioritized within the KEP. Usually organs travel 
rather than donors, except in the Netherlands, Slovakia 
and Switzerland, where the donors travel according to 
the protocol. Simultaneous surgeries for exchanges are 
required everywhere by protocol, except in the Czech 
Republic and Poland due to large exchanges and lack of 
operating theaters, respectively.
In most countries, there are national guidelines for 
donors and recipients to enter the KEP. All the donors 
and recipients are fully assessed before inclusion in a 
KEP and in some countries special rules apply for clini-
cally complex donors. Usually large countries have mul-
tiple laboratories to carry out crossmatch testing and 
smaller countries use 1 laboratory only. In all of the 
KEPs the exchanges/chains are identified after a virtual 
crossmatch and then these are confirmed in a labora-
tory crossmatch. Most countries have nationally agreed 
definitions of HLA incompatibility and a commonly 
used mean fluorescence intensity threshold (between 
2000 and 3000). Almost all countries consider results 
from historical samples as well, but the current ones are 
deemed most relevant. The practice regarding formal 
arrangements for reimbursing the expenses and loss of 
earnings of living donors varies between countries, but 
the countries with the most advanced KEPs have cost 
neutral reimbursement policies.
The algorithms which match recipients with donors 
mostly aim to maximize the number of transplants, in 
combination with a variety of other criteria. In many 
countries the optimization considers the HLA-match 
between donors and recipients and/or blood type compat-
ibility. Blood type identical transplants can be prioritized. 
Additionally, algorithms might look for smaller donor-
recipient age-differences and travel distances (coming 
from the same region). In the United Kingdom, donor-
donor age difference is used as a tie-breaker between pos-
sible matches. The sensitization and the waiting time of 
the patient can also matter. Shorter exchange cycles are 
generally preferred in the solution.
We summarize these and other main features of the 
European KEPs in Table 1. We also included general data 
on the transplant activity of the countries covered in our 
survey in Table 2 and Table 3.
Overview of Activity beyond Europe
There are several countries outside Europe where KEPs 
are operational, for example, in South Korea, United States, 
Canada, and Australia. For further information, we refer 
to 2 recent surveys25,26 on KEPs around the world. Here, 
we include a description of the situation in the United 
States, and information on one of their nationwide KEPs, 
ie, the United Network for Organ Sharing (UNOS), which 
was established in 2010. UNOS is a partner organization 
in the ENCKEP COST Action.T
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In the United States, UNOS (which administers the 
Organ Procurement and Transplantation Network 
[OPTN]), the National Kidney Registry and the Alliance 
for Paired Donation are the 3 KEPs operating nationwide. 
In addition, many regional and single-center programs 
exist within approximately 250 living donor transplant 
centers. Seventy centers are actively participating with 
UNOS from among the 160 centers registered with this 
organization. Of note is that approximately 200 cent-
ers have conducted at least 1 transplant in an exchange 
through an internal hospital program, a regional program, 
or one of the national programs in the United States. Some 
of the large transplant centers perform the majority of 
their exchanges in-house and report only their hard-to 
match patient-donor pairs to the national programs. One 
of the organizational implications of this fragmented sys-
tem is that the national KEPs do not wait to build up their 
pools, as is common practice in Europe.
United Network for Organ Sharing conducts matching 
runs every week, and the National Kidney Registry and the 
Alliance for Paired Donation search for exchanges imme-
diately after each registration. UNOS allows 2- and 3-way 
exchanges and 4-way chains for logistical reasons. Among 
the 173 transplants performed between 2010 and 2015, 
52 were through 2-way exchanges 75 through 3-ways and 
46 through altruistic chains. The high (90%) failure rate 
is the main issue in the US system. By the end of 2015, 
UNOS had 1628 registered patients and they identified 
2246 matches in virtual crossmatch tests. Only 173 trans-
plants proceeded, which is partly due to the practice of 
centers registering only hard-to-match patients and the 
lack of consistency in the HLA laboratory testing.
Challenges and Opportunities
The survey identified the following main challenges for 
countries that do not yet operate a KEP: (1) lack of knowl-
edge about KEPs; (2) lack of software tools; (3) lack of a 
legal framework; and (4) the small size of the country.
Descriptions of existing practices, as for instance pro-
vided above, as well as the ENCKEP COST Action itself, 
improve access to information and knowledge and serve 
to address the first challenge. Software to manage and 
optimize KEPs will also be investigated by ENCKEP, and 
future reports will enhance accessibility of existing tech-
nology for new countries.
The development of legislation to allow kidney exchanges 
(and its new modalities) is a task for policy makers and 
governments, in alignment with public opinion about liv-
ing donor organ donation. Being well-informed about the 
operation and effects of existing KEPs across Europe may 
influence the beliefs and opinions of medical professionals, 
policy makers, the public and the government. Finally, as 
to the size of the country being a limitation, our results 
show that some medium-sized countries run effective KEPs 
or engage in international cooperation to this purpose.
Regarding the countries with operating KEPs, a key 
challenge reported by all countries is to maintain or 
increase the KEP pool size by encouraging new registra-
tions. This holds particularly true for HLAi or ABOi pairs 
when routinely referred for desensitization treatment (as 
is for example the case in France, Italy, and Sweden). The 
accumulation of highly HLA sensitized recipients in the 
pool is an issue for several countries, making it difficult to 
find suitable matches for immunologically complex recipi-
ents. As an example, we note that in Spain the proportion 
of highly sensitized (PRA > 75%) patients has gradually 
increased from around 20% in 2010 to 50% in 2015.
There are essentially 3 categories of opportunities to 
improve the performance of the KEPs: (1) extending 
the national pools, (2) allowing new modalities in the 
exchange, and (3) increasing international cooperation.
(1) Extending National Pools
• Reaching full coverage in the national KEPs through the 
participation of all the transplant centers.
• Inclusion of compatible pairs to achieve better HLA or 
age match for the recipients involved and generating more 
exchange opportunities for other recipients.
• Inclusion of HLA incompatible pairs in preference to anti-
body removal, and inclusion of ABO incompatible pairs to 
avoid the costs and higher risks associated with desensiti-
zation programs (at least by registering them for a num-
ber of runs in the KEP before choosing these alternative 
treatments).
• Inclusion of altruistic (unspecified) donors to trigger KEP 
chains, where the transplants can be nonsimultaneous and 
in the form of long or “never ending” chains.
• Allowing multiple potential donors to register for 1 patient 
to improve the chances of identifying exchange cycles.
TABLE 2.
General information about the kidney transplantation activities of the 17 countries covered in the survey for 2016, Part A
 Austria Belgium
Czech 
Republic France Italy Netherlands Poland Portugal Spain UK
Population of country (million) 8.6 11.4 10.5 64.7 59.8 17 38.6 10.3 46.1 65.1
Total number of kidney transplants 432 520 458 3615 2076 991 1108 499 2997 3328
No. deceased kidney transplants 365 453 412 3039 1796 426 1058 434 2654 2310
No. living kidney transplants 67 67 46 576 280 565 50 65 343 1018
No. ABOi transplants nd nd nd 67* 53** Nd 1** nd 33** 57*
No. patients on dialysis 4451 nd 6668** 44419* nd 6452* 21000 12458 27727 28000*
No. active patients on waiting lists 587 813 506** 17698 6830 629 1069 2011 4309 5215
Part a countries with operating KEPs.
Data is from Newsletter Transplants,6 except the information denoted by * and ** that were not included in Reference 6, which are taken from the returned questionnaires for years 2015 (*) and 2016 
(**), respectively. nd indicates we had no data provided from either of the two sources.
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(2) Allowing New Modalities in the Exchange
• Extending the length of simultaneous exchange cycles and 
nonsimultaneous chains.
• Considering HLAi and ABOi transplantations for hyper-
immunized patients, for them to receive a kidney that is 
immunologically better than his/her original donor’s, with 
the help of desensitization treatment.
• Improving the effectiveness of the selection of exchanges 
by fine-tuning the interaction between optimization and 
the virtual and laboratory crossmatch tests. Flexibility with 
finding alternative exchanges in the light of a positive cross-
match is important to maximize transplants.
• Establishing an optimal run frequency. Depending upon the 
dynamics of the pool, finding the right frequency may fur-
ther enhance the performance of the KEP.
(3) Increasing International Cooperation
There are a number of different models for current 
international collaborations and plans: some are led by 
an advanced KEP, whereas other countries are joining 
together their small pools to create larger pools. In the 
United Kingdom, patient-donor pairs from Ireland are 
welcome to participate, and 6 recipients have already 
received transplants. Spain, with the second largest KEP in 
Europe, has started cooperation with Italy and Portugal. 
The Netherlands helped to establish the Belgian KEP by 
sharing their software. France and Switzerland signed 
a KEPs convention in 2015, but to date no run has suc-
ceeded in identifying matched pairs. France is also in 
negotiation with Belgium. Austria and the Czech Republic 
have already joined their pools and performed their first 
transnational exchange in September 2016,28 followed by 
a 3-way kidney exchange on December 5, 2017, involving 
2 pairs in Prague and 1 in Vienna. Based on the Swedish 
initiative, Scandiatransplant has just started the coordi-
nation of a joint KEP involving Denmark, Norway, and 
Sweden. Eurotransplant is helping with the organization of 
the Belgian KEP and, theoretically, it is possible for a resi-
dent of a Eurotransplant country to join a KEP in another 
Eurotransplant country. International Collaboration is an 
opportunity that in turn poses new challenges. It requires 
many legislative, medical, financial, and ethical issues to 
be resolved. As the example of deceased organ sharing 
networks (such as Eurotransplant and Scandiatransplant) 
shows, such international cooperation is feasible and can 
be beneficial for all stakeholders, and especially the highly 
sensitized patients.
DISCUSSION
This study provides a comprehensive review of the state 
of the art of European KEPs in LDKT, identifying their 
key characteristics and their main challenges. Our findings 
clearly reveal the complexity of the (interorganizational) 
structures and processes involved in KEPs. It appears that 
there is a considerable diversity among KEPs in participat-
ing countries, each having been developed in a different 
context and taking its own approach to address country-
specific challenges. The most advanced programs with a 
longer history have experience of how to advance by con-
tinuous review and improvement. The emerging/develop-
ing programs can learn from these advancements as well as 
from other early stage programs to develop a model that is T
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suitable for their requirements. Recognizing the differences 
in ethical viewpoints, legal frameworks, clinical practices, 
geography, population size, et cetera, it is clear that solu-
tions that appear to work best in one country may be sub-
optimal in another and vice versa. One “model” does not 
fit all.
The same differences between systems imply that col-
laboration in the form of transnational KEPs adds new 
complexities regarding ethical, legal, clinical, and financial 
frameworks of the countries involved. New principles, con-
ditions and objectives are called for to ensure that collab-
oration appropriately benefits all populations, recipients 
and donors involved. Such collaboration may particularly 
benefit the growing number of highly sensitized patients 
who are hard to match nationally.
Recommendations for National KEPs
Based on our study we have identified the following key 
characteristics that define KEP effectiveness:
• a transparent, objective, and responsible donor selec-
tion system, including both physical and psychological 
screening;
• consistent and responsive systems and processes including 
matching software, immunological testing, organizational 
framework, and central coordination;
• clinical leadership to establish confidence in the KEP as the 
treatment of choice for immunologically complex recipi-
ents and compatible recipient-donor pairs seeking a better 
age or HLA match and to ensure that recipients and donors 
are appropriately informed about their treatment options;
• recipient and donor awareness to inform their decision-
making and encourage participation in the KEP;
• a centralized follow up system, to monitor the effectiveness 
of the program in terms of the impact on the donor and 
recipient, and more generally in terms of overall outcomes;
• a culture of continuous improvement to develop the KEP 
in response to innovations in the field, clinician, and patient 
choice, and to actively manage potential risks (eg, diminishing 
pool size, nonproceeding transplants, low uptake of the KEP).
Future Work
Based on the trends observed in the development of 
European KEPs, we expect that new national programs 
to be established and that countries with operating KEPs 
will advance their programs according to the opportunities 
described above. In particular, we believe that more coun-
tries will permit altruistic donors to trigger long chains as 
part of the proposed exchanges, more countries will allow 
the participation of compatible donors in the programs by 
providing quality guarantees for these patients, and desen-
sitization treatment will be better coordinated with the 
KEPs.
Besides the improvement of the national programs, we 
expect the ongoing international collaborations to extend 
rapidly, partly facilitated by our ENCKEP COST Action, 
in particular for:
• sharing knowledge and expertise to support new, emerging, 
and developing programs;
• effective cross-border collaborations to improve pool size 
and optimization;
• advanced cross-border schemes to maximize options 
for immunologically complex recipients who remain 
unmatched within their own country KEPs.
Our ENCKEP network continues to conduct scientific 
research in an international and interdisciplinary collabo-
ration on KEPs. The next steps are to identify best prac-
tices in modeling and optimization aspects of the KEPs, 
and to address the ethical and legal challenges of (inter)
national KEPs.
As effective KEPs ultimately benefit all patients, we hope 
that the presented detailed description of current KEP 
practices will guide advances in practice, foster interna-
tional cooperation, and promote access to transplantation 
for the growing population of ESRD patients.
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